Loss of IGF2 imprinting:: A potential marker of colorectal cancer risk

被引：571

作者：

Cui, HM

Cruz-Correa, M

Giardiello, FM

Hutcheon, DF

Kafonek, DR

Brandenburg, S

Wu, YQ

He, XB

Powe, NR

Feinberg, AP

机构：

[1] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA

[2] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA

[3] Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA

[4] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA

来源：

SCIENCE | 2003年 / 299卷 / 5613期

关键词：

D O I：

10.1126/science.1080902

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Loss of imprinting (LOI), an epigenetic alteration affecting the insulin-like growth factor II gene (IGF2), is found in normal colonic mucosa of about 30% of colorectal cancer (CRC) patients, but it is found in only 10% of healthy individuals. In a pilot study to investigate the utility of LOI as a marker of CRC risk, we evaluated 172 patients at a colonoscopy clinic. The adjusted odds ratio for LOI in lymphocytes was 5.15 for patients with a positive family history [95% confidence interval (95% CI), 1.70 to 16.96; probability P = 0.002], 3.46 for patients with adenomas (95% CI, 1.14 to 11.37; P = 0.026), and 21.7 for patients with CRC (95% CI, 3.48 to 153.6; P = 0.0005). LOI can be assayed with a DNA-based blood test, and it may be a valuable predictive marker of an individual's risk for CRC.

引用

页码：1753 / 1755

页数：3

共 17 条

[1] Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability [J].